SPRB (Spruce Biosciences) Change In Receivables : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Spruce Biosciences Change In Receivables?

Spruce Biosciences's change in receivables for the quarter that ended in Dec. 2024 was $0.00 Mil. It means Spruce Biosciences's Accounts Receivable stayed the same from Sep. 2024 to Dec. 2024 .

Spruce Biosciences's change in receivables for the fiscal year that ended in Dec. 2024 was $0.00 Mil. It means Spruce Biosciences's Accounts Receivable stayed the same from Dec. 2023 to Dec. 2024 .

Spruce Biosciences's Accounts Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Spruce Biosciences's Days Sales Outstanding for the three months ended in Dec. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Spruce Biosciences's liquidation value for the three months ended in Dec. 2024 was $22.37 Mil.

Spruce Biosciences Change In Receivables Historical Data

The historical data trend for Spruce Biosciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spruce Biosciences Change In Receivables Chart

Spruce Biosciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

Spruce Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Spruce Biosciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Spruce Biosciences (NAS:SPRB) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Spruce Biosciences's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.697	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Spruce Biosciences's accounts receivable are only considered to be worth 75% of book value:

Spruce Biosciences's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	38.753	-	16.388	+	0.75 * 0	+	0.5 * 0
=	22.37

Spruce Biosciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of Spruce Biosciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Spruce Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spruce Biosciences Inc (NAS:SPRB) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

611 Gateway Boulevard, Suite 740, South San Francisco, CA, USA, 94080

Website

https://www.sprucebiosciences.com

Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).

Executives

Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Percival Barretto-ko	director	611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO CA 94080
Niall O'donnell	director	C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105
Charlton Ralph William Iii	officer: Chief Medical Officer	2001 JUNIPERO SERRA BOULEVARD, SUITE 640, DALY CITY CA 94104
Javier B. Szwarcberg	director, officer: Chief Executive Officer	2001 JUNIPERO SERRA BOULEVARD, SUITE 640, DALY CITY CA 94014
Kirk Ways	director	C/O 2001 JUNIPERO SERRA BOULEVARD, SUITE 540, DALY CITY CA 94014
Camilla V Simpson	director	20 ELAINE AVE., MILL VALLEY CA 94941
Jonas Hansson	director	18 AVENUE D'OUCHY, LAUSANNE V8 CH-1006
Bali Muralidhar	director	C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077
Healthcap Viii, L.p.	10 percent owner	18 AVENUE D'OUCHY, C/O HEALTHCAP VIII GP SA, CH 1006 LAUSANNE V8 1006
Rivervest Venture Fund Iii (ohio), L.p.	10 percent owner	11000 CEDAR AVENUE, SUITE 100, CLEVELAND OH 44106-3502
Moghrabi Dina Chaya	director	22 GLEDHOW GARDENS, FLAT 2, LONDON X0 SW5 0AZ
Omega Fund Vi Gp Manager, Ltd.	10 percent owner	888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Omega Fund Vi Gp, L.p.	10 percent owner	888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Richard King	director, officer: Chief Executive Officer	C/O KOS PHARMACEUTICALS INC, 1001 BRICKELL AVE 25TH FL, MIAMI FL 33131